Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PMM2 | O15305 | 1/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.39 |
| ▸ | PHOSPHO1 | Q8TCT1 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2343332 | 0.88 | FGFR1 (0.45) | NPSR1KDM4EMAPTHTTSMN1; SMN2 | |
| SCHEMBL29954953 | 0.87 | KDM4E (0.52) | NPSR1KDM4EMAPTHTTSMN1; SMN2 | |
| SCHEMBL2343158 | 0.87 | KDM4E (0.52) | NPSR1KDM4EMAPTHTTSMN1; SMN2 | |
| SCHEMBL2341920 | 0.87 | MAPT (0.48) | NPSR1KDM4EMAPTHTTSMN1; SMN2 | |
| SCHEMBL2343043 | 0.87 | MAT2A (0.39) | NPSR1KDM4EMAPTHTTSMN1; SMN2 | |
| SCHEMBL2351229 | 0.87 | MEN1 (0.42) | NPSR1MAPTHTTSMN1; SMN2NOD2 | |
| SCHEMBL2348590 | 0.85 | CYP1A2 (0.46) | NPSR1HTTSMN1; SMN2FGFR1POLB | |
| SCHEMBL2345150 | 0.84 | NPSR1 (0.49) | NPSR1KDM4EMAPTHTTSMN1; SMN2 | |
| SCHEMBL2349601 | 0.84 | LMNA (0.40) | KDM4ESMN1; SMN2ALDH1A1LMNAPOLB | |
| SCHEMBL27651983 | 0.84 | LMNA (0.38) | NPSR1KDM4EMAPTHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008491-B2 | poly(adenosine 5'-diphosphate ribose) polymerase inhibitors such as 1-phenyl-2-(piperazin-1-yl)-1,3-dihydropyrrolo[2,3-b]pyridine-3-carboxaldehyde, used in the treatment and/or prevention central nervous system and cardiovascular disorders | AVENTIS PHARMACEUTICALS, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20080255350-A1 | SUBSTITUTED AZA-INDOLES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-7405300-B2 | Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) | AVENTIS PHARMAVEUTICALS INC. (US) | 2008-07-29 | — | — | US | disclosed |
| CN-1870991-A | Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) | AVENTIS PHARMA INC (US) | 2006-11-29 | — | — | CN | disclosed |
| EP-1663202-A1 | SUBSTITUTED INDOLES AS INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) | Aventis Pharmaceuticals, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005023246-A1 | SUBSTITUTED INDOLES AS INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054631-A1 | Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054631-A1 | Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) | PARP1, PARP11, PARP3 | NPSR1 496/4885KDM4E 1305/4885GAA 2614/4885 |
| US-20080255350-A1 | SUBSTITUTED AZA-INDOLES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | PARP1, PARP11, PARP15 | NPSR1 650/4885KDM4E 273/4885GAA 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.